The city of Washington, District Of Columbia, currently has 164 active clinical trials seeking participants for Cancer research studies.
Clinical Trial of Approaches to Prostate Cancer Surgery
Recruiting
This is a prospective, randomized controlled trial to compare cancer control and health-related quality of life following pelvic fascia-sparing radical prostatectomy versus standard radical prostatectomy. The investigators hypothesize that pelvic fascia-sparing radical prostatectomy will have similar cancer control (primary outcome) and sexual function outcomes; and significantly better urinary function, penile shortening/deformity and inguinal hernia risks as compared to radical prostatectomy.
Gender:
Male
Ages:
Between 40 years and 80 years
Trial Updated:
04/22/2024
Locations: Georgetown University, Washington, District of Columbia
Conditions: Prostate Cancer
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
Recruiting
This study is being done to understand how many people with HIV (PWH) present for cancer care across the AIDS Malignancy Consortium in the United States and if there are reasons that some PWH choose to participate, or not in cancer clinical trials. Optional quality of life surveys will be used to learn more about how HIV and cancer and HIV and cancer treatment affect people.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: George Washington University Cancer Center, Washington, District of Columbia
Conditions: HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma, AIDS-related Kaposi Sarcoma, AIDS-Related Malignancy, Anal Cancer, HPV-Related Malignancy
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Recruiting
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Recruiting
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or b... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: Kaiser Permanente-Capitol Hill Medical Center, Washington, District of Columbia +1 locations
Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
Recruiting
The goal of this clinical trial is to test MGC018 in patients with relapsed or refractory Extensive-Stage Small-Cell Lung Cancer (ES-SCLC). The main question it aims to answer is: • Does the administration of MGC018 achieve a clinically meaningful response rate of 25% in patients with relapsed or refractory ES-SCLC? Participants enrolled in the trial will receive MGC018 through an intravenous (IV) infusion, every 28 days until disease progression or unacceptable toxicity. Tumor assessment will... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia +1 locations
Conditions: Extensive-stage Small-cell Lung Cancer
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
Recruiting
The Cancer Experience Registry®: An Online Survey Research Study to Understand the Experiences of Those Impacted By a Cancer Diagnosis. The Registry is a web-based platform to distribute cross-sectional and longitudinal surveys. Study surveys are designed based on input from advisor experts, including patients and caregivers, and focus on the social, emotional, physical, financial and decision-making experiences of those who have been diagnosed with cancer and their caregivers. Findings contribu... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Cancer Support Community Research & Training Institute, Washington, District of Columbia
Conditions: Neoplasms, Cancer, Caregiver
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Recruiting
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observa... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia +1 locations
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
mHealth for Young Adult Cancer Survivors
Recruiting
We aim to refine and pilot test an 8-week phone- and app-based intervention to promote hope, and thereby mitigate life disruption caused by cancer diagnosis and treatment, among young adults (YAs); our proposal involves (Aim 1) formative research among YA survivors and healthcare providers; and (Aim 2) an randomized controlled trial (RCT) of the intervention vs. attention control among 150 YA cancer survivors. The proposed research is innovative in its use of: 1) a novel intervention target - ho... Read More
Gender:
All
Ages:
Between 20 years and 39 years
Trial Updated:
04/06/2024
Locations: George Washington University, Washington, District of Columbia
Conditions: Survivorship, Cancer, Psychological Well-Being
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Recruiting
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1 as a single agent therapy.
Gender:
All
Ages:
12 years and above
Trial Updated:
04/04/2024
Locations: Georgetown University Medical Center, Washington, District of Columbia
Conditions: Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Recruiting
A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth alone or in combination with abiraterone in men with metastatic prostate cancer.
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: Clinical Trial Site, Washington, District of Columbia
Conditions: Prostate Cancer Metastatic
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
Recruiting
This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/22/2024
Locations: Research Site, Washington, District of Columbia
Conditions: Non-Small Cell Lung Cancer
A Study of CDX-585 in Patients With Advanced Malignancies
Recruiting
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: George Washington University Cancer Center, Washington, District of Columbia
Conditions: Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors